A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)-Reference-Cited by-同舟云学术

A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)

Published:2006-08 Issue:8 Volume:8 Page:465-473
ISSN:1098-3600
Container-title:Genetics in Medicine
language:en
Short-container-title:Genetics in Medicine

Author:

Muenzer Joseph,Wraith James E.,Beck Michael,Giugliani Roberto,Harmatz Paul,Eng Christine M.,Vellodi Ashok,Martin Rick,Ramaswami Uma,Gucsavas-Calikoglu Muge,Vijayaraghavan Suresh,Wendt Suzanne,Puga Antonio,Ulbrich Brian,Shinawi Marwan,Cleary Maureen,Piper Diane,Conway Ann Marie,Kimura Alan

Publisher

Elsevier BV

Subject

Genetics (clinical)

Reference36 articles.

1. The mucopolysaccharidoses;Neufeld;The metabolic and molecular bases of inherited disease,2001

Cited by 485 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rapid genotyping of inversion variants in Mucopolysaccharidosis type II using long-range PCR: A case report;Molecular Genetics and Metabolism Reports;2024-12

2. Evaluation of early treatment with intravenous idursulfase and intrathecal idursulfase‐IT on cognitive function in siblings with neuronopathic mucopolysaccharidosis II;Journal of Inherited Metabolic Disease;2024-09-09

3. Genotype–phenotype findings in patients with mucopolysaccharidosis II from the Hunter Outcome Survey;Molecular Genetics and Metabolism;2024-09

4. Intravenous Idursulfase for the Treatment of Mucopolysaccharidosis Type II: A Systematic Literature Review;International Journal of Molecular Sciences;2024-08-06

5. Opportunities for nanomaterials in enzyme therapy;Journal of Controlled Release;2024-08